Traditional Chinese medicine suppresses left ventricular hypertrophy by targeting extracellular signal-regulated kinases signaling pathway in spontaneously hypertensive rats

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Xiong, Xingjiang ^a   Yang, Xiaochen ^a   Duan, Lian ^a   Liu, Wei ^b   Zhang, Yun ^a   Liu, Yongmei ^a   Wang, Pengqian ^a   Li, Shengjie ^c   Li, Xiaoke ^d  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; HERBACEOUS AGENT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN C FOS; RAS PROTEIN;

ANIMAL; BLOOD PRESSURE; DRUG EFFECT; GENETICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; MALE; METABOLISM; PATHOLOGY; RAT; SIGNAL TRANSDUCTION; SPONTANEOUSLY HYPERTENSIVE RAT; WISTAR KYOTO RAT;

ANIMALS; BLOOD PRESSURE; BRAIN-DERIVED NEUROTROPHIC FACTOR; DRUGS, CHINESE HERBAL; HEART RATE; HYPERTROPHY, LEFT VENTRICULAR; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROTO-ONCOGENE PROTEINS C-FOS; RAS PROTEINS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; SIGNAL TRANSDUCTION;

EID: 85013648198     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep42965     Document Type: Article

References (93)

1. Sliwa, K., Stewart, S. & Gersh, B. J. Hypertension: a global perspective. Circulation 123, 2892-2896 (2011).
2. Guo, F., He, D., Zhang, W. & Walton, R. G. Trends in prevalence, awareness, management, and control of hypertension among United States adults, 1999 to 2010. J Am Coll Cardiol 60, 599-606 (2012).
3. Aronow, W. S. et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Am Coll Cardiol 57, 1-78 (2011).
4. Kearney, P. M. et al. Global burden of hypertension: analysis of worldwide data. Lancet 365, 217-223 (2005).
5. McManus, R., Caulfield, M. & Williams, B. NICE hypertension guideline 2011: evidence based evolution. BMJ 344, e181 (2012).
6. Ruilope, L. M. Current challenges in the clinical management of hypertension. Nat Rev Cardiol 9, 267-275 (2012).
7. Redfield, M. M. et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289, 194-202 (2003).
8. Cuspidi, C., Sala, C., Negri, F., Mancia, G. & Morganti, A. on behalf of the Italian Society of Hypertension. Prevalence of leftventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens 26, 343-349 (2012).
9. Larstorp, A. C. K. et al. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study. J Hum Hypertens 25, 178-185 (2011).
10. Gupta, S. et al. Left ventricular hypertrophy, aortic wall thickness, and lifetime predicted risk of cardiovascular disease: the dallas heart study. J Am Coll Cardiol Img 3, 605-613 (2010).
11. Bombelli, M. et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens 27, 2458-2464 (2009).
12. Cowan, B. R. & Young, A. A. Left ventricular hypertrophy and renin-angiotensin system blockade. Curr Hypertens Rep 11, 167-172 (2009).
13. Okin, P. M. et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292, 2343-9 (2004).
14. Pierdomenico, S. D. & Cuccurullo, F. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am J Hypertens 23, 876-881 (2010).
15. Wang, Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 116, 1413-1423 (2007).
16. Wilkins, B. J. et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94, 110-118 (2004).
17. Kehat, I. & Molkentin, J. D. Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann Ny Acad Sci 1188, 96-102 (2010).
18. Elrod, J. W. et al. Cyclophilin D controls mitochondrial pore-dependent Ca (2+) exchange, metabolic flexibility, and propensity for heart failure in mice. J Clin Invest 120, 3680-3687 (2010).
19. Kehat, I. et al. Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth. Circ Res 108, 176-183 (2011).
20. Ferreira, A. J. et al. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases. Exp Physiol 96, 287-294 (2010).
21. Dominic C. H. et al. Opposing actions of extracellular signal-regulated kinase (ERK) and signal transducer and activator of Transcription 3 (STAT3) in regulating microtubule stabilization during cardiac hypertrophy. J Biol Chem 286, 1576-1587 (2011).
22. Xiong, X. J. Integrating traditional Chinese medicine into Western cardiovascular medicine: an evidence-based approach. Nat Rev Cardiol 12, e374 (2015).
23. Xiong, X. J. et al. Chinese herbal formulas for treating hypertension in traditional Chinese medicine: perspective of modern science. Hypertens Res 36, 570-579 (2013).
24. Xiong, X. J., Borrelli, F., Ferreira, A. S. Ashfaq, T. & Feng, B. Herbal medicines for cardiovascular diseases. Evid Based Complement Alternat Med 2014, e809741 (2014).
25. Yang, X. C., Xiong, X. J. & Wang, J. Clinical observation of 108 cases of primary hypertension treated with bu shen jiang ya therapy. World J Integr Tradit West Med 9, 1083-1086 (2014).
26. Liu, W., Wang, J., Xiong, X. J. & Yang, X. C. Experimental study of bu shen jiang ya decoction on acute toxicology. Beijing J Tridit Chin Med 32, 647-649 (2013).
27. Yang, X. C., Xiong, X. J., Zhang, Y., Liu, Y. M. & Wang, J. Impacts of bu shen jiang ya formula on adiponectin and insulin resistance in spontaneously hypertensive rats. World J Integr Tradit West Med 8, 1107-1110 (2013).
28. Wang, J. & Xiong, X. J. Evidence-based Chinese medicine for hypertension. Evid Based Complement Alternat Med 2013, e978398 (2013).
29. Wang, J. Wang, P. Q. & Xiong, X. J. Current situation and re-understanding of syndrome and formula syndrome in Chinese medicine. Int Med 2, e1000113 (2012).
30. Luiz, A. B., Cordovil, I., Filho, J. B. & Ferreira, A. S. Zangfu zheng (patterns) are associated with clinical manifestations of zang shang (target-organ damage) in arterial hypertension. Chin Med 6, 23 (2011).
31. Xiong, X. J. et al. Trends in the treatment of hypertension from the perspective of traditional Chinese medicine. Evid Based Complement Alternat Med 2013, e275279 (2013).
32. Wang, J. & Xiong, X. J. Current situation and perspectives of clinical study in integrative medicine in China. Evid Based Complement Alternat Med 2012, e268542 (2012).
33. Wang, J., Xiong, X. J. & Liu, W. Traditional Chinese medicine syndromes for essential hypertension: a literature analysis of 13, 272 patients. Evid Based Complement Alternat Med 2014, e418206 (2014).
34. Wang, J. & Xiong, X. J. Control strategy on hypertension in Chinese medicine. Evid Based Complement Alternat Med 2012, e284847 (2012).
35. Wang, J. & Xiong, X. J. Outcome measures of Chinese herbal medicine for hypertension: an overview of systematic reviews. Evid Based Complement Alternat Med 2012, e697237 (2012).
36. Yang, X. C., Xiong, X. J. & Wang, J. Application of kidney-nourishing herbal medicine for treating hypertension. China J Chin Mater Med 38, 4015-4019 (2013).
37. Yang, X. C., Xiong, X. J. & Wang, J. Application of kidney-nourishing herbal medicine for treating hypertension with insulin resistance. Chin J Integr Tradit Chin West Med 34, 637-640 (2014).
38. Angell, S. Y., Cock, K. M. D. & Frieden, T. R. A public health approach to global management of hypertension. Lancet 385, 825-827 (2015).
39. Neal, B., MacMahon, S. & Chapman, N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356, 1955-1964 (2000).
40. Chobanian, A. V. et al. And The National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
41. Psaty, B. M. et al. Health outcomes associated with anti-hypertensive therapies used as first-line agents: asystematic review and metaanalysis. JAMA 277, 739-745 (1997).
42. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373, 2103-2116 (2015).
43. Wang, J., Xiong, X. J. & Yang, X. C. Is it a new approach for treating senile hypertension with kidney-tonifying Chinese herbal formula? a systematic review of randomized controlled trials. Evid Based Complement Alternat Med 2014, e473038 (2014).
44. Wang, J. et al. Chinese patent medicine liu wei di huang wan combined with antihypertensive drugs, a new integrative medicine therapy, for the treatment of essential hypertension: a systematic review of randomized controlled trials. Evid Based Complement Alternat Med 2012, e714805 (2012).
45. Julius, S. Autonomic nervous system dysregulation in human hypertension. Am J Cardiol 67, 3B-7B (1991).
46. Benetos, A., Rudnichi, A., Thomas, F., Safar, M. & Guize, L. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension 33, 44-52 (1999).
47. Prasad, V. K. et al. Association of exercise heart rate response with incidence of hypertension in men. Mayo Clin Proc 89, 1101-1107 (2014).
48. Gillman, M. W., Kannel, W. B., Belanger, A. & D'Agostino, R. B. Influence of heart rate on mortality among persons with hypertension: The Framingham Study. Am Heart J 125, 1148-1154 (1993).
49. Palatini, P. et al. For the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 162, 2313-2321 (2002).
50. Ryu, M., Bayasgalan, G., Kimm, H., Nam, C. M. & Ohrr, H. Association of resting heart rate and hypertension stages on all-cause and cardiovascular mortality among elderly Koreans: the Kangwha Cohort Study. J Geriatr Cardiol 13, 573-579 (2016).
51. Zhang, L. H., Xiao, P. G., Huang, Y. & Qian, Y. K. Advances in pharmacology and clinical research of paeonol. Chin J Integr Trad West Med 16, 187-190 (1996).
52. Frohlich, E. D. et al. The heart in hypertension. N Engl J Med 327, 998-1008 (1992).
53. Brandt, M. C. et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 59, 901-909 (2012).
54. Lieke, E. et al. Dietary fish oil improves endothelial function and lowers blood pressure via suppression of sphingolipid-mediated contractions in spontaneously hypertensive rats. J Hypertens 32, 1050-1058 (2014).
55. Sudesh, V., Carol, A. F., Sushil, P., Linda, L. & Veeresh, G. Dietary α-lipoic acid supplementation lowers blood pressure in spontaneously hypertensive rats. J Hypertens 18, 567-573 (2000).
56. Zhang, N. B., Huang, Z. G., Cui, W. D. & Ding, B. P. Effects of puerarin on expression of cardiac Smad3 and Smad7 mRNA in spontaneously hypertensive rat. J Ethnopharmacol 138, 737-740 (2011).
57. Kim, D. D., Sanchez, F. A., Duran, R. G., Kanetaka, T. & Duran, W. N. Endothelial nitric oxide synthase is a molecular vascular target for the Chinese herb Danshen in hypertension. Am J Physiol Heart Circ Physiol 292, 2131-2137 (2007).
58. Wang, B. et al. Effect of traditional Chinese medicine Qin-Dan-Jiang-Ya-Tang on remodeled vascular phenotype and osteopontin in spontaneous hypertensive rats. J Ethnopharmacol 110, 176-182 (2007).
59. Shih, H. C., Lee, T. H., Chen, S. C., Li, C. Y. & Shibuya, T. Anti-hypertension effects of traditional Chinese medicine Ju-ling-tang on renal hypertensive rats. Am J Chin Med 33, 913-921 (2005).
60. Ng, C. F. et al. The anti-hypertensive effect of Danshen (Salvia miltiorrhiza) and Gegen (Pueraria lobata) formula in rats and its underlying mechanisms of vasorelaxation. J Ethnopharmacol 137, 1366-1372 (2011).
61. Duarte, J. et al. Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. Brit J Pharmacol 133, 117-124 (2001).
62. Han, F. et al. Inhibition of dystrophin breakdown and endothelial nitric-oxide synthase uncoupling accounts for cytoprotection by 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate (DY-9760e) in left ventricular hypertrophied mice. J Pharmacol Exp Ther 332, 421-428 (2010).
63. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 25, 402-408 (2001).
64. Chang, D. M., Yue, S. H., Liu, H. X., Yang, Y. T. & Niu, G. P. Effect of Rehmannia on blood pressure in rats. J Xinxiang Med Coll 6, 9-11 (1989).
65. Cai, C. C., Wang, H. X. & Wang, S. Effect of rehmannia glutinosa polysaccharide on the serum GLP-1 and GIP levels in obese diabetic rat model. Chin J Gerontol 33, 4506-4507 (2013).
66. Zhang, R. et al. Ameliorating effect and potential mechanism of rehmannia glutinosa oligosaccharides on the impared glucose metabolism in chronic stress rats fed with high-fat diet. Phytomedicine 21, 607-614 (2014).
67. Guo, X. N., Zhang, R. X., Jia, Z. P., Li, M. X. & Wang, J. Effects of Rehmannia glutinosa oligosaccharides on proliferation of 3T3-L1 adipocytes and insulin resistance. China J Chin Mater Med 31, 403-407 (2006).
68. Han, J. C., Ji, H., Xue, C. F., Yin, M. & Lou, F. C. Hypoglycemic effect of terpenes from fructus corni. Chin J Nat Med 4, 125-129 (2006).
69. Yamabe, N., Kang, K. S., Goto, E., Tanaka, T. & Yokozawa, T. Beneficial effect of Corni Fructus, a constituent of Hachimi-jio-gan, on advanced glycation end-product-mediated renal injury in streptozotocin-treated diabetic rats. Biol Pharm Bull 30, 520-526 (2007).
70. Yokozawa, T. et al. Protective effects of morroniside isolated from Corni Fructus against renal damage in streptozotocin-induced diabetic rats. Biol Pharm Bull 31, 1422-1428 (2008).
71. Qi, M. Y., Liu, H. R., Dai, D. Z., Li, N. & Dai, Y. Total triterpene acids, active ingredients from Fructus Corni, attenuate diabetic cardiomyopathy by normalizing ET pathway and expression of FKBP12.6 and SERCA2a in streptozotocin-rats. J Pharm Pharmacol 60, 1687-1694 (2008).
72. Liu, H., Xu, H. Q. & Shi, Y. Protecting effect of total iridoid glycoside in Fructus Corni Officinalis on insulin resistance and blood lipid level of rats with type 2 diabetic cardiopathy. Pharmacol Clin Chin Mater Med 23, 36-39 (2007).
73. Hao, H. P., Xu, H. Q., Zhu, Q., Pi, W. X. & Pan, Y. Effects of iridoside of corni fructus on NO, NOS, and ET in rats with diabetic vascular complications. J Nanjing Tradit Chin Med Univ 19, 157-158 (2003).
74. Luo, L. F. et al. Antihypertensive effect of Eucommia ulmoides Oliv. extracts in spontaneously hypertensive rats. J Ethnopharmacol 129, 238-243 (2010).
75. Gu, J. et al. Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling. J Ethnopharmacol 133, 6-13 (2011).
76. Li, Z. Y. et al. Hypertensive cardiac remodeling effects of lignan extracts from Eucommia ulmoides Oliv. bark-a famous traditional Chinese medicine. Am J Chin Med 41, 801-815 (2013).
77. Park, S. A. et al. Hypoglycemic and hypolipidemic action of Du-zhong (Eucommia ulmoides Oliver) leaves water extract in C57BL/ KsJ-db/db mice. J Ethnopharmacol 107, 412-417 (2006).
78. Lee, M. K. et al. Hypoglycemic effect of Du-zhong (Eucommia ulmoides Oliv.) leaves in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 67, 22-28 (2005).
79. Jin, X. et al. Ameliorative effect of Eucommia ulmoides Oliv. leaves extract (ELE) on insulin resistance and abnormal perivascular innervation in fructose-drinking rats. J Ethnopharmacol 128, 672-678 (2010).
80. Liu, W., Wang, L., Yu, J., Asare, P. F. & Zhao, Y. Q. Gastrodin Reduces Blood Pressure by Intervening with RAAS and PPAR? in SHRs. Evid Based Complement Alternat Med 2015, e828427 (2015).
81. Kho, M. C. et al. Gastrodia elata Ameliorates High-Fructose Diet-Induced Lipid Metabolism and Endothelial Dysfunction. Evid Based Complement Alternat Med 2014, e101624 (2014).
82. Lee, O. H., Kim, K. I., Han, C. K., Kim, Y. C. & Hong, H. D. Effects of acidic polysaccharides from gastrodia rhizome on systolic blood pressure and serum lipid concentrations in spontaneously hypertensive rats fed a high-fat diet. Int J Mol Sci 13, 698-709 (2012).
83. Pan, C. et al. Panax notoginseng and its components decreased hypertension via stimulation of endothelial-dependent vessel dilatation. Vascul Pharmacol 56, 150-158 (2012).
84. Liu, J. J. & Chen, R. Effects of Panax notoginseng saponins on plasma vWF, t-PA and PAI-1 in paitents with hypertension. Med J Qilu 22, 221-222 (2007).
85. Chen, Y. B. & Dong, Y. H. Clinical effect and pharmacological analysis of panax notoginseng saponins in the treatment of hyperlipidmia. China Med Pharm 6, 51-53, 139 (2006).
86. Zhang, J. Y., Zhao, L., Li, Y. K. & Weng, W. L. Effect of paeonol on blood pressure and blood flow in artery of spontaneously hypertensive rats and its mechanisms related on vasomotion. China J Chin Mater Med 40, 4903-4907 (2015).
87. Ha, T. et al. Selected compounds derived from Moutan Cortex stimulated glucose uptake and glycogen synthesis via AMPK activation in human HepG2 cells. J Ethnopharmacol 131, 417-424 (2010).
88. Lau, C. H. et al. Pharmacological investigations of the anti-diabetic effect of Cortex Moutan and its active component paeonol. Phytomedicine 14, 778-784 (2007).
89. Walker, A. F. et al. Hypotensive effects of hawthorn for patients with diabetes taking prescription drugs: a randomised controlled trial. Br J Gen Pract 56, 437-443 (2006).
90. Dalli, E. et al. Crataegus laevigata decreases neutrophil elastase and has hypolipidemic effect: a randomized, double-blind, placebocontrolled trial. Phytomedicine 18, 769-775 (2011).
91. Wang, J., Xiong, X. J. & Feng, B. Effect of crataegus usage in cardiovascular disease prevention: an evidence-based approach. Evid Based Complement Alternat Med 2013, e149363 (2013).
92. Dan, H. et al. Hypolipidemic effects of Alismatis rhizome on lipid profile in mice fed high-fat diet. Saudi Med J 32, 701-707 (2011).
93. Li, Q. & Qu, H. B. Study on the hypoglycemic activities and metabolism of alcohol extract of Alismatis Rhizoma. Fitoterapia 83, 1046-1053 (2012).